BiomX is at the forefront of developing innovative phage therapies aimed at targeting and eradicating harmful bacteria associated with chronic diseases. The company specializes in creating both natural and engineered phage cocktails tailored to specific bacterial strains, particularly focusing on conditions such as cystic fibrosis and diabetic foot osteomyelitis. Their proprietary BOLT platform employs advanced computational tools and experimental validation to optimize these phage cocktails, ensuring they possess complementary functions that enhance their efficacy against antibiotic-resistant bacteria. This approach not only aims to improve patient outcomes but also addresses the growing challenge of antibiotic resistance by utilizing the natural predatory capabilities of bacteriophages.

In addition to phage therapy, BiomX has developed the XMarker platform, which leverages metagenomics to discover predictive microbial genomic signatures that can serve as biomarkers for various medical conditions, including inflammatory bowel disease (IBD). This platform combines high-resolution DNA analysis with artificial intelligence and cloud computing to create highly sensitive and specific classifiers. Collaborations with major pharmaceutical companies like Janssen and Boehringer Ingelheim further enhance the potential of the XMarker platform, as it seeks to identify biomarkers that can stratify patient responses to therapies, ultimately paving the way for more personalized and effective treatment strategies.

United States

BiomX (NYSE America: PHGE) is developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

BiomX

Company Details